Pharmacologic and Non-Pharmacologic Alternatives for POTS

First-Line Pharmacologic Alternatives

The American College of Cardiology recommends midodrine as the most studied first-line vasoconstrictor alternative for POTS patients who cannot tolerate or fail pyridostigmine, with dosing at 2.5-10 mg, taken in the morning before rising and last dose no later than 4 pm, to avoid supine hypertension 1, 2
Midodrine increases peripheral vascular resistance through arteriolar and venous constriction, particularly beneficial for neuropathic POTS phenotype, with side effects including pilomotor reactions, pruritus, supine hypertension, bradycardia, gastrointestinal symptoms, and urinary retention 3
Beta-blockers show the largest reduction in heart rate variability and are particularly effective for hyperadrenergic POTS phenotype, with propranolol and bisoprolol demonstrating comparable efficacy, but may worsen fatigue 1, 3

Fludrocortisone stimulates renal sodium retention and expands fluid volume, particularly beneficial for hypovolemic POTS phenotype, with dosing at 0.1-0.3 mg once daily, but may cause supine hypertension, edema, hypokalemia, headache, and more serious reactions with doses >0.3 mg daily 4, 5
Ivabradine is recommended for symptomatic patients with inappropriate sinus tachycardia and POTS, alone or in combination with beta-blockers, with a mechanism of selective heart rate reduction without negative inotropic effects, but this indication is not FDA-approved 6, 2

The European Society of Cardiology recommends optimizing non-pharmacologic interventions, including volume expansion strategies, such as salt supplementation at 6-9 g per day and fluid intake targeting 2-3 liters per day, before or concurrent with pharmacotherapy 5, 4
Physical countermeasures, such as leg crossing, stooping, squatting, and tensing muscles, and gradual staged movements with postural change, are recommended to reduce venous pooling and improve orthostatic tolerance 3
Compression garments, such as abdominal binders and/or support stockings, reduce venous pooling and are recommended for patients with POTS 4, 2

For hyperadrenergic POTS, beta-blockers are recommended as first-line pharmacotherapy, with central sympatholytics as alternatives 2
For neuropathic POTS, midodrine is recommended as first-line to enhance vascular tone, with pyridostigmine as alternative and droxidopa as third-line 1, 2
For hypovolemic POTS, volume expansion is recommended as primary intervention, with fludrocortisone if non-pharmacologic volume expansion is insufficient, and exercise reconditioning is critical 4, 5

The American College of Cardiology guideline addresses pyridostigmine specifically for neurogenic orthostatic hypotension (NOH) and does not extend the recommendation to postural orthostatic tachycardia syndrome (POTS). 7

According to the same guideline, syncope occurs relatively infrequently in POTS, and there is little evidence that syncope is directly caused by POTS itself. 7